Nuclear expression of Y‐box binding protein‐1 is associated with poor prognosis in patients with pancreatic cancer and its knockdown inhibits tumor growth and metastasis in mice tumor models
Open Access
- 3 March 2016
- journal article
- tumor markers-and-signatures
- Published by Wiley in International Journal of Cancer
- Vol. 139 (2) , 433-445
Abstract
The objective of this study was to examine the implication of Y‐box‐binding protein‐1 (YB‐1) for the aggressive phenotypes, prognosis and therapeutic target in pancreatic ductal adenocarcinoma (PDAC). YB‐1 expression in PDAC, pancreatic intraepithelial neoplasia (PanIN) and normal pancreas specimens was evaluated by immunohistochemistry, and its correlation with clinicopathological features was assessed in patients with PDAC. The effects of YB‐1 on proliferation, invasion and expressions of cell cycle‐related proteins and matrix metalloproteinases (MMPs) were analyzed by WST‐8, cell cycle and Matrigel invasion assays, Western blotting and quantitative RT‐PCR in PDAC cells transfected with YB‐1‐siRNAs. To verify the significance of YB‐1 for tumor progression in vivo, the growth and metastasis were monitored after intrasplenic implantation of ex vivo YB‐1 siRNA‐transfected PDAC cells, and YB‐1‐targeting antisense oligonucleotides were intravenously administered in nude mice harboring subcutaneous tumor. The intensity of YB‐1 expression and positivity of nuclear YB‐1 expression were higher in PDAC than PanIN and normal pancreatic tissues. Nuclear YB‐1 expression was significantly associated with dedifferentiation, lymphatic/venous invasion and unfavorable prognosis. YB‐1 knockdown inhibited cell proliferation via cell cycle arrest by S‐phase kinase‐associated protein 2 downregulation and consequent p27 accumulation, and decreased the invasion due to downregulated membranous‐type 2 MMP expression in PDAC cells. Tumor growth and liver metastasis formation were significantly suppressed in nude mice after implantation of YB‐1‐silenced PDAC cells, and the YB‐1 targeting antisense oligonucleotide significantly inhibited the growth of subcutaneous tumors. In conclusion, YB‐1 may be involved in aggressive natures of PDAC and a promising therapeutic target.Keywords
Funding Information
- Japan Science and Technology Agency (14524896)
This publication has 47 references indexed in Scilit:
- Mutual Regulation between Raf/MEK/ERK Signaling and Y-Box–Binding Protein-1 Promotes Prostate Cancer ProgressionClinical Cancer Research, 2013
- Pancreatic Cancer Surgery in the New MillenniumAnnals of Surgery, 2011
- Hypoxia activates the hedgehog signaling pathway in a ligand‐independent manner by upregulation of Smo transcription in pancreatic cancerCancer Science, 2011
- Molecular Decoy to the Y-Box Binding Protein-1 Suppresses the Growth of Breast and Prostate Cancer Cells whilst Sparing Normal Cell ViabilityPLOS ONE, 2010
- The expression of activated Y-box binding protein-1 serine 102 mediates trastuzumab resistance in breast cancer cells by increasing CD44+ cellsOncogene, 2010
- YB-1 alters MT1-MMP trafficking and stimulates MCF-7 breast tumor invasion and metastasisBiochemical and Biophysical Research Communications, 2010
- Y-box binding protein-1 (YB-1) promotes cell cycle progression through CDC6-dependent pathway in human cancer cellsEuropean Journal of Cancer, 2010
- The pleiotropic functions of the Y‐box‐binding protein, YB‐1BioEssays, 2003
- Increased nuclear localization of transcription factor YB-1 in acquired cisplatin-resistant ovarian cancerJournal of Cancer Research and Clinical Oncology, 2002
- Cellular Activation of MMP-2 (Gelatinase A) by MT2-MMP Occurs via a TIMP-2-independent PathwayJournal of Biological Chemistry, 2001